Method for producing compound

By simplifying the synthesis route and using diastereoisomer salt separation technology, the problem of reduced efficiency of Parkinson's disease treatment drugs after long-term use is solved, and large-scale production with high yields and low cost is achieved.

CN118908964APending Publication Date: 2024-11-08H LUNDBECK AS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410957226.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-05-20
Filing Date
2020-05-19
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing Parkinson's disease treatment drugs are less efficient after long-term use, and large-scale production methods are inefficient, making it difficult to meet the demand for high yields.

Method used

A new method has been developed to manufacture (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7 -diol and (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol[4',5' :5,6]benzo[1,2-g]quinoline synthesis route simplifies the process, improves yields, and reduces reagent and waste use through the resolution of diastereoisomer salts.

Benefits of technology

The simplification of the synthesis route has been achieved, the total yield of compounds has been improved, and the overall production rate is suitable for large-scale production, reducing production costs and environmental impacts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908964A_ABST
    Figure CN118908964A_ABST
Patent Text Reader

Abstract

The present invention relates to a novel process for the manufacture of (6aR, 10aR)-7-propyl-6, 6a, 7, 8, 9, 10, 10a, 11-octahydro-[1, 3] dioxo-penta [4 ', 5': 5, 6] benzo [1, 2-g] quinoline of formula (Ib), (4aR, 10aR)-1-propyl-1, 2, 3, 4, 4a, 5, 10, 10a-octahydro-benzo [g] quinoline-6, 7-diol of formula (I) and the salts thereof. The two compounds are useful in the treatment of neurodegenerative diseases and disorders, such as Parkinson's disease. The invention also relates to novel intermediate compounds of said process. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the Chinese invention patent application with application date of May 19, 2020 and application number 202080036363.4. Technical Field

[0002] The present invention relates to a method for producing (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and (6aR, 10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol[4',5':5,6]benzo[1,2-g]quinoline and salts thereof, which are compounds for use in the treatment of neurodegenerative diseases and disorders such as Parkinson's disease. The present invention also relates to novel intermediates of the method. Background Art

[0003] Parkinson's disease (PD) is a common neurodegenerative disorder that becomes increasingly common with age, and affects an estimated 7 million to 10 million people in the world. Parkinson's disease is a multifaceted disease characterized by both motor symptoms and non-motor symptoms. Motor symptoms include resting tremor (tremor), bradykinesia / akinesia (slowness and difficulty of movement), muscle rigidity, postural instability and gait dysfunction; while non-motor symptoms include neuropsychiatric disorders (such as depression, psychotic symptoms, anxiety, emotional indifference, mild cognitive impairment and dementia) and autonomic dysfunction and sleep disorders (Poewe et al., Nature Review [Natural Review], (2017) Vol. 3 Article 17013: 1-21).

[0004] A key hallmark of Parkinson's disease pathophysiology is the loss of pigmented dopaminergic neurons in the substantia nigra pars compacta, which provide dopaminergic innervation to the striatum and other brain regions. This progressive neurodegeneration results in a decrease in striatal levels of dopamine, which ultimately leads to a series of changes in the basal ganglia circuitry, culminating in the development of the four cardinal motor features of Parkinson's disease. The primary targets of dopamine in the striatum consist of medium-sized multispiny GABAergic neurons (MSNs), which selectively express either D1 or D2 receptors awaiting targeted projection. GABAergic MSNs that project to the lateral globus pallidus (also known as the striato-pallidal 'indirect pathway') express D2 receptors (MSN-2); whereas GABAergic MSNs that project to the substantia nigra pars reticulata and medial globus pallidus (also known as the striato-nigra 'direct pathway') express D1 receptors (MSN-1). Depletion of dopamine due to neuronal loss results in unbalanced activity of the two pathways, leading to a significant reduction in thalamic and cortical output activity and, ultimately, motor dysfunction (Gerfen et al., Science (1990) 250: 1429-32; Delong, (1990) Trends in Neuroscience 13: 281-5; Alexander et Crutcher, (1990) Trends in Neuroscience 13: 266-71; and for review, Poewe et al., Nature Review (2017) Vol. 3 Article 17013: 1-21).

[0005] The most effective treatment strategies available for patients with Parkinson's disease and aimed at controlling motor symptoms are mainly indirect and direct dopamine agonists. The classic standard and gold standard treatment regimen includes chronic oral intake of L-3,4-dihydroxyphenylalanine (L-DOPA), which is decarboxylated in the brain to form dopamine. Other methods are to administer dopamine receptor agonists (such as apomorphine, which works on both D1 and D2 receptor subtypes, or pramipexole, ropinirole, etc., which are mainly directed against the D2 receptor subtype). The acceptable motor relief obtained with L-DOPA and apomorphine is due to their activation of both D1 and D2 receptor subtypes, and overall rebalancing of the indirect-direct pathway (i.e., while the D2 agonist only reverses the indirect pathway dysfunction).

[0006] L-DOPA and apomorphine have the structures depicted below and are currently the most effective PD drugs in clinical use.

[0007]

[0008] L-DOPA is a prodrug of dopamine and remains the most effective drug for the treatment of motor Parkinson's disease. However, after a few years of treatment (i.e., the honeymoon period), complications arise due to the inherent progression of the disease (persistent loss of dopaminergic neurons) and the poor pharmacokinetic (PK) profile of L-DOPA. Those complications include: 1) dyskinesia, which is abnormal involuntary movement that occurs during the optimal "duration effect" of the drug; and 2) off fluctuations, during which the positive effects of L-DOPA disappear and symptoms reappear or worsen (Sprenger and Poewe, CNS Drugs [CNS Drugs] (2013), 27: 259-272).

[0009] Direct dopamine receptor agonists can activate dopamine autoreceptors and postsynaptic dopamine receptors located on medium spiny neurons MSN-1 and MSN-2. Apomorphine belongs to a class of dopamine agonists with 1,2-dihydroxybenzene (catechol) moieties. When combined with phenylethylamine motifs, catecholamines generally have low oral bioavailability or no oral bioavailability, as is the case with apomorphine. Although it is delivered non-orally (typically intermittent subcutaneous administration via a pump or continuous parenteral infusion during the day), apomorphine is used clinically in PD therapy. For apomorphine, animal studies have shown that transdermal delivery or implants can provide possible forms of administration. However, when apomorphine was studied in monkeys from the delivery of implants (Bibbiani et al., Chase Experimental Neurology [experimental neurology] (2005), 192: 73-78), it was found that in most cases, animals must be treated with the immunosuppressant dexamethasone to prevent local irritation and other complications after implantation surgery. Alternative delivery strategies for apomorphine therapy in PD, such as inhaled and sublingual formulations, have been extensively developed (see, e.g., Grosset et al., Acta Neurol Scand. (2013), 128:166-171 and Hauser et al., Movement Disorders (2016), Vol. 32(9):1367-1372). However, these efforts have not yet been used clinically to treat PD.

[0010] An alternative approach to non-oral formulation of catecholamines involves the use of prodrugs that mask the free catechol hydroxyl groups to enable oral administration. However, a known problem associated with the development of prodrugs for clinical use is the difficulty associated with predicting conversion to the parent compound in humans.

[0011] Different ester prodrugs of catecholamines have been reported in the literature, such as enteric-coated N-propyl-noraporphine (NPA) and monopivaloyl esters of apomorphine for duodenal delivery (see, e.g., WO 02 / 100377) and the D1-like agonist adralide (diacetyl prodrug of A-86929) (Giardina and Williams; CNS Drug Reviews (2001), Vol. 7(3):305-316). In humans, adralide undergoes extensive hepatic first-pass metabolism after oral administration and, as a result, has a low oral bioavailability (approximately 4%). In PD patients, intravenous (IV) adralide has antiparkinsonian efficacy comparable to that of L-DOPA (Giardina and Williams; CNS Drug Reviews (2001), Vol. 7(3):305-316).

[0012] In addition to ester prodrugs of catecholamines, an alternative prodrug approach involves masking the two catechol hydroxyl groups as corresponding methylenedioxy derivatives or di-acetal derivatives. This prodrug principle has been described, for example, in Campbell et al., Neuropharmacology (1982); 21(10):953-961 and in US4543256, WO 2009 / 026934 and WO 2009 / 026935.

[0013] For catecholamine prodrugs, yet another proposed approach is to form enone derivatives, as suggested in, for example, WO 2001 / 078713 and Liu et al., Bioorganic Med. Chem. (2008), 16: 3438-3444. For further examples of catecholamine prodrugs, see, for example, Sozio et al., Exp. Opin. Drug Disc. (2012); 7(5): 385-406.

[0014] The compound (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol, depicted as the following compound (I), is disclosed in WO 2009 / 026934. The trans isomer was previously disclosed in Liu et al., J. Med. Chem. (2006), 49: 1494-1498 and then in Liu et al., Bioorganic Med. Chem. (2008), 16: 3438-3444, which included pharmacological data indicating that the compound had low oral bioavailability in rats. The racemate was first disclosed in Cannon et al., J. Heterocyclic Chem. (1980); 17: 1633-1636.

[0015]

[0016] Compound (I) is a dopamine receptor agonist with mixed D1 and D2 activities. Three prodrug derivatives of Compound (I) are known in the art.

[0017] Liu et al., J. Med. Chem. (2006), 49: 1494-1498 and Liu et al., Bioorganic Med. Chem. (2008), 16: 3438-3444 disclosed the enone derivatives having formula (Ia) depicted below, which were shown to be converted into active compounds (I) in rats.

[0018]

[0019] WO 2009 / 026934 and WO 2009 / 026935 disclose two types of prodrug derivatives of compound (I), including a compound (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol[4',5':5,6]benzo[1,2-g]quinoline having the following formula (Ib):

[0020]

[0021] It has been demonstrated in WO 2010 / 097092 that compound (Ib) is converted to compound (I) in rat and human hepatocytes. In addition, the in vivo pharmacology of compounds (Ia) and (Ib) and the active "parent compound" (I) has been tested in different animal models for Parkinson's disease (WO 2010 / 097092). Compound (I) and both compounds (Ia) and (Ib) were found to be effective, indicating that compounds (Ia) and (Ib) are converted to compound (I) in vivo. All three compounds have been reported to have a longer duration of action than that observed for L-dopa and apomorphine.

[0022] Other prodrugs of compound (I) disclosed in WO 2009 / 026934 and WO 2009 / 026935 are conventional ester prodrugs having the formula (Ic):

[0023]

[0024] Despite long-standing interest in the field, there clearly remains an unmet need for the development of effective, well-tolerated and active drugs for the treatment of PD.

[0025] Therefore, there is also a need for methods for manufacturing such drugs, especially methods suitable for large-scale production resulting in high yields of product.

[0026] WO 2009 / 026934 discloses a method for preparing compound (I) and a method for preparing compound (Ib) from compound (I). These methods include multiple steps and use chiral chromatography to obtain separated enantiomers, and are therefore not optimal for large-scale production.

[0027] Therefore, there remains a need for improved processes for the large-scale production of compounds (I) and (Ib). Summary of the invention

[0028] The inventors of the present invention have developed a new method for preparing (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (Compound (I)) and (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol[4',5':5,6]benzo[1,2-g]quinoline (Compound (Ib)). The process of the present invention for making compound (I) provides several advantages over the process previously described in WO 2009 / 026934, including 1) a short synthetic route; 2) an improved overall yield of compound (I); 3) the use of resolution via diastereomeric salts rather than resolution by supercritical fluid chromatography (SFC), which is uneconomical and not suitable for large-scale production; and 4) resolution early in the synthetic route rather than later as described in WO 2009 / 026934, which reduces the amount of reagents / solvents required and the amount of waste generated.

[0029] One aspect of the present invention relates to a method for preparing a compound having the following formula (Ib): (6aR, 10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol-[4',5':5,6]benzo[1,2-g]quinoline

[0030]

[0031] A novel method for producing (4aR, 10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol and its salts having the following formula (I):

[0032]

[0033] Another aspect of the present invention also provides a novel method for preparing (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol[4',5':5,6]benzo[1,2-g]quinoline (Compound (Ib)) and its salt.

[0034] Further separate aspects relate to novel intermediates of the process. Accordingly, one aspect of the present invention provides a compound having the following formula (A2) or a salt thereof.

[0035]

[0036] Another aspect of the present invention provides a compound having the following formula (A3) or a salt thereof.

[0037]

[0038] Still another aspect of the present invention provides a compound having the following formula (A4) or a salt thereof.

[0039]

[0040] Still another aspect of the present invention provides a compound having the following formula (A5) or a salt thereof.

[0041]

[0042] Still another embodiment of the present invention provides a compound having the following formula (a2i) or a salt thereof.

[0043]

[0044] Still another aspect of the present invention provides a compound having the following formula (a2ii) or a salt thereof.

[0045]

[0046] definition

[0047] Mentioned compounds

[0048] References to compound (I), compound (Ib), compound (A1), compound (A2), compound (A3), compound (A4) or compound (A5) include the compound in solution and the solid form of the compound, including the free substance of the compound (e.g., zwitterion), the salt of the compound (e.g., acid addition salt or base addition salt), and polymorphic and amorphous forms of the compounds of the present invention and their salts. In addition, the compounds and their salts may potentially exist in unsolvated form as well as in solvated form with solvents such as water, ethanol, etc.

[0049] Sometimes, a specific salt form is indicated for a compound, for example like (A2-hemi-L-tartrate) indicates the hemi-L-tartrate salt of compound (A2). In the present context, reference to a compound as a "free base": compound (I), compound (Ib), compound (A1), compound (A2), compound (A3), compound (A4) or compound (A5) is intended to indicate that the compound is in non-salt form.

[0050] Pharmaceutically acceptable salts

[0051] In the context of the present invention, pharmaceutically acceptable salts are intended to indicate non-toxic, ie physiologically acceptable salts.

[0052] The term "pharmaceutically acceptable salt" includes pharmaceutically acceptable acid addition salts, which are salts formed with inorganic and / or organic acids at the nitrogen atom in the parent molecule. The acid can be selected from, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, malonic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, gentisic acid, saccharin, and sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, naphthalene-2-sulfonic acid, 2-hydroxyethanesulfonic acid and benzenesulfonic acid.

[0053] Further examples of useful acids and bases that form pharmaceutically acceptable salts can be found, for example, in Stahl and Wermuth (eds.) “Handbook of Pharmaceutical salts. Properties, selection, and use”, Wiley-VCH, 2008.

[0054] Compounds (Ib), (A1), (A2), (A3), (A4) and (A5) can be used as intermediates for the manufacture of compound (I) or a pharmaceutically acceptable salt thereof. Therefore, the salt forms of compounds (Ib), (A1), (A2), (A3), (A4) and (A5) are not limited to their pharmaceutically acceptable salts. Nevertheless, pharmaceutically acceptable salts of compounds (Ib), (A1), (A2), (A3), (A4) and (A5) can also be advantageously used in the manufacture of compound (I). Therefore, in one embodiment of the invention, the salts of compounds (Ib), (A1), (A2), (A3), (A4) and / or (A5) are pharmaceutically acceptable salts.

[0055] Chemical Manufacturing

[0056] In the present context, a compound "derived from chemical manufacture" indicates that the compound has been manufactured by an ex vivo chemical method such as, but not limited to, one of the methods described in the experimental section herein. The terms "manufactured" and "chemically manufactured" can be used interchangeably.

[0057] Therefore, in an embodiment of the present invention, compound (I) is produced by an ex vivo chemical method.

[0058] In another embodiment of the present invention, compound (Ib) is produced by in vitro chemical methods. DETAILED DESCRIPTION

[0059] The present invention relates to a novel method for preparing (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol (compound (I)) by using compound (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxol[4',5':5,6]benzo-[1,2-g]quinoline (compound (Ib)). The present invention also relates to a novel method for preparing compound (Ib).

[0060] Compound (Ib) is a prodrug of compound (I), which is a dual dopamine agonist with mixed D1 and D2 activities and can be used to treat neurodegenerative diseases and disorders such as Parkinson's disease. WO 2009 / 026934 discloses a method for making compound (I) and an additional method for making compound (Ib) from compound (I).

[0061] The inventors of the present invention have discovered a new and improved process for the manufacture of two compounds, wherein compound (Ib) is used as an intermediate in the manufacture of compound (I).

[0062] The overall method is briefly described in Scheme 1 below.

[0063] Starting material (A1): tert-butyl 4-(6-chlorobenzo[d][1,3]dioxol-5-yl)-3-oxobutanoate can be prepared using known methods, such as the method described by Brückner and co-workers in Synthesis 2008, 14: 2229-2246, or as described below.

[0064] Starting material (a5i): 2-(Benzo[d][1,3]dioxol-5-yl)acetonitrile is commercially available.

[0065] Option 1: Holistic approach

[0066]

[0067] Table 1: List of names of isolated intermediates and other compounds:

[0068]

[0069]

[0070]

[0071]

[0072]

[0073] Step 0)

[0074] In step 0), an enamine intermediate compound (a2i) is formed. The following two alternative steps with different starting compounds can be used to form the intermediate compound a2i:

[0075] Step 0 sub-step (i), wherein a ketoester (tert-butyl 4-(6-chlorobenzo[d][1,3]dioxol-5-yl)-3-oxobutanoate) compound (A1) is reacted with 3-chloropropane-1-amine in situ to convert the enamine intermediate compound (a2i) using a catalytic amount of zinc chloride.

[0076] Step 0 Sub-step S1 is an alternative step to the above sub-step (i), wherein compound (a6i) is subjected to a Blaise reaction with tert-butyl 2-bromoacetate and zinc, then treated with acetic acid, and then treated with 3-chloropropane-1-amine hydrochloride to obtain compound (a2i). In sub-step S1, compound (a2i) is directly and conveniently formed from compound (a6i).

[0077] In one embodiment of the present invention, sub-step S1 comprises isolating compound (a2i).

[0078] Available SO 2 Cl 2 Commercially available compound (a5i) is chlorinated to provide compound (a6i) in high yield. 2 Cl 2 Compound (a5i) is chlorinated to provide compound (a6i). In even more specific embodiments of the present invention, the compound (a5i) is chlorinated with SO 2 Cl 2 Compound (a5i) is chlorinated to provide compound (a6i), followed by step 0 sub-step S1 to provide compound (a2i).

[0079] Step 0' An alternative route from compound (a6i) to the starting material compound (A1) is provided:

[0080] Available SO 2 Cl 2 Commercially available compound (a5i) is chlorinated to provide compound (a6i) in high yield. Compound (a6i) can then be converted to compound (A1) or (a2i), depending on the reaction conditions.

[0081] To form compound (A1), compound (a6i) is subjected to a Bryce reaction with tert-butyl 2-bromoacetate and zinc, and after aqueous acidic hydrolysis, compound (A1) is produced.

[0082] In one embodiment of the present invention, step 0' is used to obtain compound (A1), followed by step 0 sub-step (i) to form compound (a2i).

[0083] Step 1)

[0084] In step 1), compound (a2i) is converted into the desired enantiomer compound (A2) or compound (A2-hemi-L-tartrate) by two alternative routes.

[0085] Generally, it is expected that the presence of a primary alkyl chloride and an amine functional group in the same molecule will promote the alkylation of the amine, which in the present case will lead to the formation of an azetidine. However, it was unexpectedly found that despite the presence of a primary alkyl chloride and an amine functional group in the same molecule, compounds (a2ii) and (A2) have good stability because they do not readily form the corresponding azetidine (a3i) or (a3ii) (see below), respectively, or undergo self-condensation.

[0086]

[0087] Step 1, sub-step (ii) followed by sub-step (iii):

[0088] In addition, the inventors have surprisingly found that in sub-step (iii), the crude compound (a2ii) can be separated by using L-tartaric acid in a solvent (e.g., a solvent selected from MeOH, EtOH, and an aqueous mixture thereof) to form diastereomeric salts in high yield, thereby providing the separated amine (A2) (A2-half-L-tartrate) as a half-L-tartrate with a high enantiomeric excess of more than 95% (e.g., >99.5%), while also resulting in high yield. Therefore, in one embodiment of the present invention, sub-step (ii) is used to obtain compound (a2i), and compound (a2i) is subsequently used in sub-step (iii) to provide (A2-half-L-tartrate).

[0089] In sub-step (ii), sodium cyanoborohydride (NaBH 3 CN), sodium triacetoxyborohydride (STAB), 5-ethyl-2-methylpyridine borane (PEMB) or NaBH 4 Reduction of the enamine intermediate (a2i) provides the crude product (a2ii). In a particular embodiment of the invention, sodium cyanoborohydride is used to carry out sub-step (ii).

[0090] Alternatively, in step 1 sub-step (ii), compound (a2i) can be reduced to compound (a2ii) with a platinum catalyst (preferably platinum on carbon) in a suitable solvent (eg Me-THF) in the presence of hydrogen.

[0091] In one embodiment of the present invention, sub-step (ii) is carried out using a platinum catalyst at a temperature of about 20°C to about 100°C (such as about 50°C to about 80°C, such as about 55°C to about 65°C, such as about 57°C, or about 58°C, or about 59°C, or about 60°C, or about 61°C, or about 62°C or about 63°C).

[0092] In one embodiment of the invention, sub-step (ii) is carried out using a platinum catalyst at a pressure of about 2 bar to about 10 bar, such as about 2 bar to about 6 bar, such as about 3 bar to about 5 bar, such as about 4 bar.

[0093] In one embodiment of the present invention, sub-step (ii) is carried out using a platinum catalyst at a temperature of about 50°C to about 80°C and a pressure of about 2 bar to about 6 bar.

[0094] In a more specific embodiment of the present invention, sub-step (ii) is carried out using a platinum catalyst at a temperature of about 60°C and a pressure of about 4 bar.

[0095] In one embodiment of the invention, the same pot is then used to prepare the mixture using, for example, NaBH 3 CN, sodium triacetoxyborohydride (STAB), 5-ethyl-2-methylpyridine borane (PEMB), or NaBH 4 Compound (a2i) as obtained from step 0 sub-step (i) above is reduced to provide crude (a2ii).

[0096] In sub-step (iii), compound (a2ii) is resolved using L-tartaric acid in a solvent (e.g., a solvent selected from MeOH, EtOH, and aqueous mixtures thereof) to provide resolved amine (A2) as a hemi-L-tartrate salt (A2-hemi-L-tartrate).

[0097] In one embodiment of the invention, the same pot is then used to prepare the mixture using, for example, NaBH 3 CN, sodium triacetoxyborohydride (STAB), 5-ethyl-2-methylpyridine borane (PEMB), or NaBH 4 Compound (a2i) as obtained from step 0 sub-step (i) above is reduced to provide crude compound (a2ii), and the provided crude compound (a2ii) is then resolved in sub-step (iii) to obtain compound (A2-hemi-L-tartrate).

[0098] In an even more specific embodiment of the present invention, compound (a2i) as obtained from step 0 sub-step (i) above is then reduced using sodium cyanoborohydride in the same pot to provide crude compound (a2ii), and the provided crude compound (a2ii) is then resolved in sub-step (iii) to obtain compound (A2-hemi-L-tartrate).

[0099] As an alternative to performing sub-step (iii) after sub-step (ii) in step 1 as described above, step 1 sub-step (iv) can be used to provide compound (A2):

[0100] In step 1 sub-step (iv), compound (a2i) can be reduced with a chiral catalyst containing rhodium, iridium or ruthenium in the presence of hydrogen and a suitable solvent to provide compound (A2).

[0101] Specifically, in step 1 sub-step (iv), compound (a2i) can be asymmetric hydrogenated using a catalyst formed from Josiphos SL-J002-2 (cas#277306-29-3) and bis(2,5-norbornadiene)rhodium(I) tetrafluoroborate (cas#36620-11-8) in the presence of hydrogen and 2,2,2-trifluoroethanol (as solvent) to provide compound (A2) with 96% enantiomeric excess and 93% yield (based on LC-MS analysis).

[0102] A more detailed overview of the sub-steps of step 0) and step 1) is given in Scheme 2 below. Scheme 2: Detailed overview of the sub-steps of step 0) and step 1)

[0103]

[0104] In one embodiment of the present invention, step 0 sub-step S1 is used to obtain compound (a2i), followed by step 1.

[0105] In another more specific embodiment of the present invention, step 1 sub-step (ii) and sub-step (iii) are carried out after step 0 sub-step S1 to obtain compound (A2-hemi-L-tartrate).

[0106] In a more specific embodiment of the present invention, step 1 sub-step (iv) is performed after step 0 sub-step S1 to obtain compound (A2).

[0107] In one embodiment of the present invention, step O' is used to obtain compound (A1).

[0108] Therefore, in a more specific embodiment of the present invention, step 0' is followed by step 0 sub-step (i) to obtain compound (a2i), and step 0 sub-step (i) is followed by step 1 sub-step (iv) to obtain compound (A2).

[0109] In a specific embodiment of the present invention, step 0' is used to obtain compound (A1) and then step 0 sub-step (i) is performed to obtain compound (a2i), and step 0 sub-step (i) is followed by sub-steps (ii) and (iii) to obtain compound (A2-hemi-L-tartrate).

[0110] In another specific embodiment of the present invention, step 0' is followed by step 0 sub-step (i) to obtain compound (a2i), and step 1 sub-step (iv) is followed by step 0 sub-step (i) to obtain compound (A2).

[0111] Step 2)

[0112] In step 2) as shown in Scheme 3 below, by using a reducing agent such as NaBH 3 CN, sodium triacetoxyborohydride (STAB), borane 5-ethyl-2-methylpyridine borane (PEMB), or a platinum catalyst supported on a support such as carbon and hydrogen), in a solvent selected from, for example, tetrahydrofuran (THF), isopropanol (IPA) or MeOH, compound (A2) or a salt thereof undergoes further reductive amination with propionaldehyde to provide compound (A3).

[0113] Solution 3: Step 2)

[0114]

[0115] In a specific embodiment of the invention, compound (A2-hemi-L-tartrate) is used in step 2 as described herein. Therefore, in a more specific embodiment of the invention, step 1 sub-step (iii) is performed after step 1 sub-step (ii) to obtain compound (A2-hemi-L-tartrate), which is then used in step 2.

[0116] In an even more specific embodiment of the present invention, step 1 sub-step (ii) is performed after step 0 sub-step S1, followed by step 1 sub-step (iii) to obtain compound (A2-hemi-L-tartrate), which is then used in step 2.

[0117] In certain embodiments, sodium triacetoxyborohydride (STAB) is used as the reducing agent in step 2.

[0118] In one embodiment of the present invention, step 2 is carried out in a solvent selected from the group consisting of tetrahydrofuran (THF), isopropyl alcohol (IPA) and MeOH. In a more specific embodiment, step 2 is carried out in THF.

[0119] Step 3)

[0120] Step 3) as shown in Scheme 4 below provides cyclization of compound (A3) under basic conditions to produce compound (A4) which can optionally be isolated as a hemi-oxalate salt (A4-hemi-oxalate), a hydrochloride salt (A4-HCl) or a hydrobromide salt (A4-HBr).

[0121]

[0122] The reaction takes place in the presence of a strong base, preferably sodium bis(trimethylsilyl)amide (NaHMDS).

[0123] In one embodiment of the present invention, step 3 is carried out using a strong base selected from the group consisting of sodium bis(trimethylsilyl)amide (NaHMDS), lithium diisopropylamide (LDA), potassium bis(trimethylsilyl)amide (KHMDS) and lithium bis(trimethylsilyl)amide (LHMDS). In a specific embodiment of the present invention, step 3 is carried out using sodium bis(trimethylsilyl)amide (NaHMDS).

[0124] Suitable solvents for step 3 are, for example, solvents selected from the group consisting of toluene, THF and mixtures thereof. In a particular embodiment of the present invention, a mixture of toluene and THF is used as solvent.

[0125] Solution 4: Step 3)

[0126]

[0127] Typically, alkylation of esters has the disadvantage of self-condensation (due to the Claisen reaction). It is expected that the leaving group (such as amine) in the β position will be easily eliminated, leaving the acrylate system. However, the inventors have found that even if the reaction is carried out at a reasonable high temperature of -10°C, the cyclization of compound (A3) is unexpectedly thorough, providing only a few self-condensation products and / or elimination products. Typically, enolates are formed from esters at cryogenic temperatures (e.g., -78°C) to avoid side reactions such as self-condensation (see, for example, Fan et al., Bioorg. Med. Chem. Lett. [Biological Organic Chemistry and Medicinal Chemistry Communications] 2008, 18: 6236-6239 and Kotsuki et al., J. Org. Chem. [Journal of Organic Chemistry] 1992, 57: 5036-5040).

[0128] In one embodiment of the present invention, compound (A4) is isolated as a hydrochloride salt compound (A4-HCl).

[0129] Unexpectedly, the inventors have found that compound (A4-HCl) can be precipitated as a powder with little or no agglomeration. These qualities further facilitate the process. Compound (A4-HCl) can be obtained by treating compound (A4) with HCl solution.

[0130] Suitable solvents for precipitating the salt of compound (A4) may be one or more solvents selected from the group consisting of MeTHF, EtOAc, isopropanol, iPrOAc, acetone, toluene, heptane, and mixtures thereof.

[0131] In a specific embodiment of the present invention, a solvent selected from the group consisting of MeTHF, EtOAc, iPrOAc, acetone, toluene, a mixture of isopropanol (iPrOH) and heptane, a mixture of iPrOAc and heptane, and a mixture of acetone and heptane is used to precipitate a salt of compound (A4), and even more specifically to precipitate compound (A4-HCl).

[0132] In a specific embodiment of the present invention, a solvent selected from the group consisting of MeTHF, a mixture of isopropyl alcohol (iPrOH) and heptane, a mixture of iPrOAc and heptane, and a mixture of acetone and heptane is used to precipitate compound (A4-HCl).

[0133] In a more specific embodiment of the present invention, a mixture of isopropanol and heptane is used to precipitate compound (A4-HCl).

[0134] In a more specific embodiment of the present invention, a mixture of acetone and heptane is used to precipitate compound (A4-HCl).

[0135] When isolating a salt of compound (A4), such as compound (A4-HCl) or compound (A4-hemi-oxalate) in the process of the present invention, alkaline release can be used to release compound (A4) before starting further synthesis steps (e.g., step 5). Therefore, in one embodiment of the present invention, a salt of compound (A4) is reacted with a suitable base (e.g., Na 2 CO 3 , K 2 CO 3 or aqueous ammonia) to obtain a solution of compound (A4) as a free base.

[0136] In a specific embodiment of the present invention, compound (A4-HCl) is reacted with a suitable base (such as Na 2 CO 3, K 2 CO 3 or aqueous ammonia) to obtain compound (A4) as a free base.

[0137] Step 4)

[0138] In step 4) as shown in Scheme 5 below, intramolecular Friedel-Crafts acylation of compound (A4) produces tricyclic compound (A5). 2 O 5 Compound (A4) is conveniently converted to compound (A5) by Friedel-Crafts acylation with a mixture of H2O and TFA in chlorobenzene.

[0139] Solution 5: Step 4)

[0140]

[0141] The inventors have discovered that compound (A5) is unexpectedly stable under acidic conditions or in the form of an acid salt and can be conveniently isolated as a tosylate salt in high yield after careful neutralization of the acidic reaction mixture (see Formula (A5-tosylate) below).

[0142]

[0143] In contrast, if compound (A5) is isolated as a free base, it will slowly undergo aromatization by eliminating the amine group to form compound (a4i) (see the formula below) in addition to other products. The formation of compound (a4i) from compound (A5) was not observed under acidic conditions, which is surprising because the nitrogen atom in compound (A5) is protonated under acidic conditions and is expected to be a better leaving group than under neutral or basic conditions.

[0144]

[0145] Therefore, in one embodiment of the present invention, step 4 comprises isolating compound (A5) as an acid salt. In a more specific embodiment of the present invention, step 4 comprises isolating compound (A5-tosylate).

[0146] Step 5)

[0147] Step 5) as shown in Scheme 6 below provides a one-pot hydrodechlorination and ketone reduction of compound (A5) or a salt thereof in the presence of a palladium catalyst (such as Pd / C) and hydrogen to produce compound (Ib).

[0148] The high efficiency of the reaction is unexpected since, in contrast to the reduction of ketones to alkanes which is promoted by acidic conditions, hydrodechlorination reactions are generally hindered under acidic conditions and instead promoted under basic conditions (Handbook of heterogeneous hydrogenation, S. Nishimura, Wiley 2001).

[0149] Solution 6: Step 5)

[0150]

[0151] In one embodiment of the present invention, compound (A5) or a salt thereof is used in step 5 to obtain compound (Ib). In another embodiment of the present invention, compound (A5-tosylate) is used in step 5 to obtain compound (Ib).

[0152] The reaction in step 5 can use different solvents, especially alcohol solvents. In one embodiment of the present invention, alcohol is used as solvent in step 5. In a more specific embodiment of the present invention, step 5 is carried out using an alcohol solvent selected from the group consisting of MeOH, EtOH, IPA and 1-propanol. In an even more specific embodiment, step 5 is carried out using EtOH as solvent.

[0153] The hydrogenation reaction in step 5 can be carried out using a palladium catalyst at a temperature ranging from about 20°C to about 100°C, such as from about 50°C to about 100°C, such as from about 60°C to about 80°C, such as about 65°C, about 67°C, or about 68°C, about 69°C, about 70°C, about 71°C, about 72°C, about 73°C, about 75°C or about 77°C.

[0154] The hydrogenation reaction in step 5 can be carried out using a palladium catalyst at a pressure ranging from about 2 bar to about 10 bar, such as about 3 bar to 6 bar, such as about 3 bar to about 5 bar, such as about 3.5 bar, or such as about 4 bar, or such as about 4.5 bar.

[0155] In a specific embodiment of the present invention, step 5 is carried out using a palladium catalyst (such as Pd / C) at a temperature of about 70°C and a pressure of about 4 bar.

[0156] Step 6)

[0157] Finally, as shown in step 6 of Scheme 7 below, a method is provided by reacting compound (Ib) with a Lewis acid or a 3 , BBr 3 The compound (Ib) or a salt thereof is converted into the compound (I) or a salt thereof by reacting with a Bronsted acid consisting of HBr.

[0158] Solution 7: Step 6)

[0159]

[0160] In a specific embodiment of the present invention, step 6 comprises reacting compound (Ib) with BCl 3 The reaction is carried out to obtain compound (I) or a salt thereof.

[0161] In another specific embodiment of the present invention, step 6 comprises reacting compound (Ib) in the form of a free base with BCl 3 The reaction is carried out to obtain compound (I) or a salt thereof.

[0162] When a salt of compound (Ib) (such as compound (Ib-L-DTTA)) is used as the starting material of step 6, alkaline release can be used to release compound (Ib) before starting further synthetic steps (such as step 6). Therefore, in one embodiment of the present invention, a salt of compound (Ib) is reacted with a base (such as Na 2 CO 3 , K 2 CO 3 or aqueous ammonia) to obtain compound (Ib) as a free base.

[0163] In a specific embodiment of the present invention, compound (Ib-L-DTTA) is reacted with a suitable base (such as Na 2 CO 3 , K 2 CO 3 or aqueous ammonia) to obtain compound (Ib) as a free base.

[0164] In an even more specific embodiment of the present invention, step 6 comprises reacting the (-)-O,O′-di-p-methylbenzoyl-L-tartrate (L-DTTA) salt of compound (Ib) with Na 2 CO 3 , K 2 CO 3 or aqueous ammonia to obtain compound (Ib) as a free base, and then compound (Ib) is reacted with BCl 3 Reaction to obtain Compound (I) or a salt thereof, such as, for example, the HCl salt of Compound (I).

[0165] Alternative routes for obtaining compound (I)

[0166] The inventors have also developed an alternative method to obtain enantiomerically pure compound (Ib) from compound (A6) or compound (A6-toluenesulfonate) in a three-step process, wherein compound (Ib) can be obtained as L-DTTA salt ((-)-O,O′-di-p-methylbenzoyl-L-tartrate), as shown in Scheme 8 below.

[0167] Scheme 8: Alternative route for obtaining compound (I)

[0168]

[0169] Alternative step 5a)

[0170] In alternative step 5a) in Scheme 8 above, compound (A6-tosylate) is converted to the free base with aqueous NaOH in Me-THF and then reacted with NaBH 4 The aqueous solution of is reduced to the free base compound (A6) in Me-THF with a yield of 85%. In step 2, the obtained compound (A7) is further reduced to compound (A8) with a yield of 90% by transfer hydrogenation, wherein the reduction is promoted by Pd / C catalyst and formic acid in an ammonium formate-MeOH-water mixture. In step 3, compound (A8) is converted into compound (Ib-L-DTTA salt) by first hydrogenating compound (A8) with Pd / C catalyst and hydrogen (adding TsOH in IPA), followed by classical resolution with L-DTTA in MeOH to produce compound (Ib-L-DTTA) with an enantiomeric excess of >99%.

[0171] Alternative Step 6)

[0172] Finally, in alternative step 6), compound (Ib-L-DTTA) is converted to the free base of compound (Ib) and reacted with BCl 3 Reprotection of the 1,2-dihydroxy moiety affords the HCl salt of compound (I) after work-up.

[0173] In contrast to this alternative method (comprising alternative step 5a, alternative step 5b and alternative 6 as shown in Scheme 8), the method comprising steps 5 and 6 of the present invention (shown in Schemes 6 and 7) provides a more convenient and efficient method because: 1) the resolution via diastereomeric salt formation is accomplished early on compound (a2ii) compared to the late resolution of compound (Ib), and 2) the hydrodechlorination and ketone reduction from compound (A5) to compound (Ib) are carried out in a single step.

[0174] Embodiments of the present invention

[0175] Further embodiments of the invention are disclosed in the following section. The first embodiment is denoted as E1, the second embodiment is denoted as E2, and so on.

[0176] E1. A method for producing a compound (I) having the following formula

[0177]

[0178] The compound is prepared from compound (Ib) having the following formula:

[0179]

[0180] E2. The method according to embodiment E1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0181] Step 0)

[0182] Sub-step (i) reacting compound (A1) with 3-chloropropane-1-amine to obtain compound (a2i); or

[0183] Sub-step (S1) reacts compound (a6i) with tert-butyl 2-bromoacetate and zinc to form a mixture, followed by

[0184] The mixture from substep (S1) is treated with acetic acid, followed by

[0185] reacting the mixture with 3-chloropropane-1-amine hydrochloride to provide compound (a2i);

[0186] Followed by

[0187] Step 1)

[0188] Sub-step (ii) reducing the compound (a2i) obtained in sub-step (i) or sub-step (S1) to obtain compound (a2ii), followed by

[0189] Sub-step (iii) resolving compound (a2ii) using L-tartaric acid to provide compound (A2-hemi-L-tartrate); or

[0190] Sub-step (iv) comprising the following steps is performed after sub-step (i) or sub-step (S1): hydrogenating the obtained compound (a2i) with a chiral catalyst in the presence of hydrogen and a solvent to provide compound (A2);

[0191] Proceed according to the following reaction scheme:

[0192]

[0193] E3. The method according to embodiment E2, wherein compound (a6i) or a salt thereof is prepared by a method comprising the step of reacting compound (a5i) or a salt thereof with a chlorinating agent

[0194]

[0195] E4. The method according to embodiment E3, wherein the chlorinating agent is sulfuryl chloride.

[0196] E5. The method according to any one of embodiments E2 to E4, wherein the reduction in step 1 sub-step (ii) occurs in the presence of a reducing agent.

[0197] E6. The method according to any one of embodiments E2 to E5, wherein the reducing agent is selected from NaBH 3 CN, sodium triacetoxyborohydride (STAB), a borane such as 5-ethyl-2-methylpyridine borane (PEMB), and NaBH 4 .

[0198] E7. The method according to any one of embodiments E2 to E6, wherein the reduction in step 1 substep (ii) occurs by using a platinum catalyst, preferably platinum on carbon.

[0199] E8. A method according to embodiments E1 to E4, wherein the chiral catalyst in step 1 sub-step (iv) is selected from (2S)-1-[(1S)-1-[bis(1,1-dimethylethyl)phosphino]ethyl]-2-(diphenylphosphino)ferrocene and bis(2,5-norbornadiene)rhodium(I) tetrafluoroborate.

[0200] E9. The method according to claims E1 to E4 and E8, wherein the solvent in step 1 sub-step (iv) is 2,2,2-trifluoroethanol.

[0201] E10. A compound having the following formula (A2)

[0202]

[0203] or a salt thereof.

[0204] E11. The compound according to embodiment E10, which is in the form of a hemi-L-tartrate salt as depicted below

[0205]

[0206] E12. Use of a compound according to any one of embodiments E10 and E11 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0207] E13. The method according to any one of embodiments E1 to E9, wherein compound (Ib) is prepared by a method comprising the following steps:

[0208] 2) according to the following reaction scheme a) or b), compound (A2) or compound (A2-semi-L-tartrate) is reacted with propionaldehyde in the presence of a reducing agent,

[0209] To provide compound (A3)

[0210] Solution a)

[0211]

[0212] Solution b)

[0213]

[0214] E14. The method according to embodiment E13, wherein compound (A3) is prepared by reacting compound (A2-hemi-L-tartrate) with propionaldehyde in the presence of a reducing agent.

[0215] E15. The method according to embodiment E14, wherein the reducing agent is selected from the group consisting of: NaBH 3 CN, sodium triacetoxyborohydride (STAB), a borane such as 5-ethyl-2-methylpyridine borane (PEMB), and a platinum catalyst, preferably platinum on carbon, and hydrogen.

[0216] E16. The method according to any one of embodiments E13 to E15, wherein the reaction occurs in a solvent selected from, for example, tetrahydrofuran (THF), isopropanol (IPA) or MeOH.

[0217] E17. A compound having the following formula (A3)

[0218]

[0219] or a salt thereof.

[0220] E18. Use of the compound according to embodiment E17 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0221] E19. The method according to embodiments E1 to E9 and E13 to E16, wherein compound (Ib) is prepared by a method comprising the following steps:

[0222] 3) Compound (A3) is reacted with a strong base according to the following reaction scheme to provide compound (A4)

[0223]

[0224] Optionally, compound (A4) is then isolated as the hemi-oxalate salt as depicted below

[0225]

[0226] E20. The method according to embodiment E19, wherein the strong base is sodium bis(trimethylsilyl)amide (NaHMDS).

[0227] E21. A method according to any one of embodiments E19 to E20, wherein the reaction between compound (A3) and the base occurs at a temperature in the range of -20°C to -5°C, such as in the range of -15°C to -5°C or such as at a temperature of about -10°C.

[0228] E22. The method according to any one of embodiments E19 to E21, wherein the compound (A4) is mixed with oxalic acid and isolated as the hemi-oxalate salt.

[0229] E23. A compound having the following formula (A4)

[0230]

[0231] or a salt thereof.

[0232] E24. The compound according to embodiment E23, which is in the form of a hemi-oxalate salt as depicted below

[0233]

[0234] E25. Use of a compound according to any one of embodiments E23 to E24 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0235] E26. The method according to embodiments E1 to E9, E13 to E16, and E19 to E22, wherein compound (Ib) is prepared by a method comprising the following steps:

[0236] 4) Intramolecular Friedel-Crafts acylation of compound (A4) was performed according to the following reaction scheme to provide compound (A5)

[0237]

[0238] Optionally, compound (A5) is subsequently isolated as a tosylate salt (A5-tosylate)

[0239]

[0240] E27. A compound having the following formula (A5)

[0241]

[0242] or a salt thereof.

[0243] E28. The compound according to embodiment E27, which is in the form of a tosylate salt as depicted below

[0244]

[0245] E29. Use of a compound according to any one of embodiments E27 to E28 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0246] E30. The method according to embodiments E1 to E9, E13 to E16, E19 to E22, and E26, wherein compound (Ib) is prepared by a method comprising the following steps:

[0247] 5) Reducing compound (A5) or a salt thereof according to the following reaction scheme to obtain compound (Ib) or a salt thereof

[0248]

[0249] E31. The method according to embodiment E30, wherein the reduction occurs by using a palladium catalyst.

[0250] E32. The method according to embodiment E1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0251] Step 0) according to any one of embodiments E2 to E4

[0252] Step 1) according to any one of embodiments E2 and E5 to E9; followed by step 2) according to any one of embodiments E13 to E16.

[0253] E33. The method according to any one of embodiments E1 to E7, wherein compound (Ib) is prepared by a method comprising the following steps:

[0254] Step 2) according to any one of embodiments E13 to E16; followed by

[0255] Step 3) according to any one of embodiments E19 to E22.

[0256] E34. The method according to any one of embodiments E1 to E7, and E11 to E13, wherein compound (Ib) is prepared by a method comprising the following steps:

[0257] Step 3) according to any one of embodiments E19 to E22; followed by

[0258] According to step 4 as described in Example E26).

[0259] E35. The method according to any one of embodiments E1 to E7, wherein compound (Ib) is prepared by a method comprising the following steps:

[0260] According to step 4 of any one of embodiments E26; followed by

[0261] Step 5) according to any one of embodiments E30 to E31.

[0262] E36. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0263] Step 0) according to any one of embodiments E2 to E4

[0264] Step 1) according to any one of embodiments E2 and E5 to E9; followed by step 2) according to any one of embodiments E13 to E16; followed by

[0265] Step 3) according to any one of embodiments E19 to E22.

[0266] E37. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0267] Step 2) according to any one of embodiments E13 to E16; followed by

[0268] Step 3) according to any one of embodiments E19 to E22; followed by

[0269] According to step 4 as described in Example E26).

[0270] E38. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0271] Step 3) according to any one of embodiments E19 to E22; followed by

[0272] According to step 4 described in Example E26); followed by

[0273] Step 5) according to any one of embodiments E30 to E31.

[0274] E39. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0275] Step 0) according to any one of Embodiments E2 to E4; followed by step 1) according to any one of Embodiments E2 and E5 to E9; followed by step 2) according to any one of Embodiments E13 to E16; followed by

[0276] Step 3) according to any one of embodiments E19 to E22; followed by

[0277] According to step 4 as described in Example E26).

[0278] E40. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0279] Step 2) according to any one of embodiments E13 to E16; followed by

[0280] Step 3) according to any one of embodiments E19 to E22; followed by

[0281] According to step 4 described in Example E26); followed by

[0282] Step 5) according to any one of embodiments E30 to E31.

[0283] E41. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0284] Step 0) according to any one of Embodiments E2 to E4; followed by step 1) according to any one of Embodiments E2 and E5 to E9; followed by step 2) according to any one of Embodiments E13 to E16; followed by

[0285] Step 3) according to any one of embodiments E19 to E22; followed by

[0286] According to step 4 described in Example E26); followed by

[0287] Step 5) according to any one of embodiments E30 to E31.

[0288] E42. The method for producing compound (I) according to any one of embodiments E1-E9, E13-E16, E19-E22, E26, and E30 to E31, wherein compound (I) is prepared from compound (Ib) by the following steps:

[0289] 6) reacting compound (Ib) with a Lewis acid or Bronsted acid selected from the group consisting of: BCl3 , BBr 3 and HBr,

[0290] To obtain compound (I)

[0291]

[0292] E43. The method according to embodiment E42, wherein step 6) is performed after step 5).

[0293] E44. A method for producing compound (I) according to any one of embodiments E35, E38, and E40 to E42, wherein after step 5)

[0294] Step 6).

[0295] E45. The method for making Compound (I) according to any one of Embodiments E1 to E9, E13 to E16, E19 to E22, E26, E30 to E31, wherein the method is an ex vivo chemical method.

[0296] E46. A compound having the following formula (a2i)

[0297]

[0298] or a salt thereof.

[0299] E47. A compound having the following formula (a2ii)

[0300]

[0301] or a salt thereof.

[0302] E48. The method of any one of embodiments E1-E9, E13-E16, E19-E22, E26 and E30-E45, wherein compound (a2i) is isolated.

[0303] E49. A method according to any one of embodiments E1-E6, E13-E16, E19-E22, E26 and E30-E45, and E48, wherein the reducing agent used in step 1 sub-step (ii) is sodium cyanoborohydride.

[0304] E50. A method according to any one of embodiments E1-E5, E7, E13-E16, E19-E22, E26, E30-E45 and E48-E49, wherein step 1 sub-step (ii) is carried out using a platinum catalyst at a temperature of about 20°C to about 100°C, such as about 50°C to about 80°C, such as about 55°C to about 65°C, such as about 57°C, or about 58°C, or about 59°C, or about 60°C, or about 61°C, or about 62°C or about 63°C.

[0305] E51. A method according to any one of embodiments E1-E5, E7, E13-E16, E19-E22, E26, E30-E45 and E48-E50, wherein step 1 sub-step (ii) is carried out using a platinum catalyst at a pressure of about 2 bar to about 10 bar, such as about 2 bar to about 6 bar, such as about 3 bar to about 5 bar, such as about 4 bar.

[0306] E52. A method according to any one of embodiments E1-E5, E7, E13-E16, E19-E22, E26, E30-E45 and E48-E51, wherein step 1 sub-step (ii) is carried out using a platinum catalyst at a temperature of about 50°C to about 80°C and a pressure of about 2 bar to about 6 bar.

[0307] E53. A method according to any one of embodiments E1-E5, E7, E13-E16, E19-E22, E26, E30-E45 and E48-E52, wherein step 1 sub-step (ii) is carried out using a platinum catalyst at a temperature of about 60°C and a pressure of about 4 bar.

[0308] E54. A method according to any one of embodiments E1-E7, E13-E16, E19-E22, E26, E30-E45 and E48-E53, wherein step 1 sub-step (iii) is carried out using an alcohol as a solvent, such as a solvent selected from MeOH, EtOH and aqueous mixtures thereof.

[0309] E55. The method according to any one of embodiments E13-E16, E19-E22, E26, E32-E33, E36-E37, E39-E45 and E48-E54, wherein the reducing agent used in step 2 is selected from NaBH 3 CN, sodium triacetoxyborohydride (STAB), a borane such as 5-ethyl-2-methylpyridine borane (PEMB), and a platinum catalyst, preferably platinum on carbon, and hydrogen.

[0310] E56. The method according to any one of embodiments E13-E16, E19-E22, E26, E32-E33, E36-E37, E39-E45 and E48-E55, wherein the reducing agent used in step 2 is sodium triacetoxyborohydride (STAB).

[0311] E57. A method according to any one of embodiments E13-E16, E19-E22, E26, E32-E33, E36-E37, E39-E45 and E48-E56, wherein step 2 is carried out in a solvent selected from the group consisting of: tetrahydrofuran (THF), isopropanol (IPA) and MeOH.

[0312] E58. The method according to any one of embodiments E13-E16, E19-E22, E26, E32-E33, E36-E37, E39-E45 and E48-E57, wherein step 2 is carried out in THF.

[0313] E59. A method according to any one of embodiments E19-E22, E26, E30-E31, E33-E34, E36-E45 and E48-E58, wherein step 3 is carried out using a strong base selected from the group consisting of: sodium bis(trimethylsilyl)amide (NaHMDS), lithium diisopropylamide (LDA), potassium bis(trimethylsilyl)amide (KHMDS) and lithium bis(trimethylsilyl)amide (LHMDS).

[0314] E60. The method according to any one of embodiments E19-E22, E26, E30-E31, E33-E34, E36-E45 and E48-E59, wherein step 3 is carried out using a solvent selected from the group consisting of: toluene, THF and mixtures thereof.

[0315] E61. A method according to any one of embodiments E19-E21, E26, E30-E31, E33-E34, E36-E45 and E48-E60, wherein step 3 subsequently separates compound (A4) into a salt selected from the group consisting of: a hemi-oxalate compound (A4-hemi-oxalate), a hydrochloride compound (A4-HCl) or a hydrobromide compound (A4-HBr).

[0316] E62. The method according to any one of embodiments E19-E21, E26, E30-E31, E33-E34, E36-E45 and E48-E61, wherein step 3 is followed by reacting compound (A4) with HCl solution and isolating the hydrochloride salt compound (A4-HCl).

[0317] E63. A method according to any one of E19-E22, E26, E30-E31, E33-E34, E36-E45 and E48-E62, wherein step 3 is followed by separating compound (A4) using a solvent selected from the group consisting of: MeTHF, EtOAc, isopropanol, iPrOAc, acetone, toluene, heptane and mixtures thereof.

[0318] E64. The method according to any one of embodiments E19-E21, E26, E30-E31, E33-E34, E36-E45 and E48-E63, wherein step 3 is followed by isolating compound (A4-HCl) using a mixture of isopropanol and heptane.

[0319] E65. The method according to any one of embodiments E19-E21, E26, E30-E31, E33-E34, E36-E45 and E48-E64, wherein step 3 is followed by isolating compound (A4-HCl) using a mixture of acetone and heptane.

[0320] E66. A method according to any one of embodiments E19-E22, E26, E30-E31, E33-E34, E36-E45 and E48-E66, further comprising a step in which the isolated salt of compound (A4) is reacted with a base to obtain compound (A4) as a free base.

[0321] E67. The method according to any one of embodiments E19-E22, E26, E30-E31, E33-E34, E36-E45 and E48-E66, further comprising wherein the salt of compound (A4) is reacted with Na 2 CO 3 , K 2 CO 3 or an aqueous solution of ammonia to obtain compound (A4) in the form of a free base.

[0322] E68. The method according to any one of embodiments E19-E22, E26, E30-E31, E34-E35, E37-E45 and E48-E67, further comprising wherein compound (A4-HCl) is reacted with Na 2 CO 3 , K 2 CO 3 or an aqueous solution of ammonia to obtain compound (A4) in the form of a free base.

[0323] E69. The method according to any one of embodiments E26, E30-E31, E34-E35, E37-E45 and E48-E68, wherein step 4 comprises isolating compound (A5) as an acid salt.

[0324] E70. The method according to any one of embodiments E26, E30-E31, E34-E35, E37-E45 and E48-E69, wherein the Friedel-Crafts acylation in step 4 is carried out using P in a suitable solvent such as chlorobenzene. 2 O 5 and TFA mixture.

[0325] E71. The method according to any one of embodiments E30-E31, E35, E38, E40-E45 and E48-E70, wherein compound (A5) or a salt thereof is used in step 5 to obtain compound (Ib).

[0326] E72. The method according to any one of embodiments E30-E31, E35, E38, E40-E45 and E48-E71, wherein compound (A5-tosylate) is used in step 5 to obtain compound (Ib).

[0327] E73. The method according to any one of embodiments E30-E31, E35, E38, E40-E45 and E48-E72, wherein an alcohol solvent is used in step 5.

[0328] E74. The method according to any one of embodiments E30-E31, E35, E38, E40-E45 and E48-E73, wherein a solvent selected from the group consisting of MeOH, EtOH, IPA and 1-propanol is used in step 5.

[0329] E75. The method according to any one of embodiments E30-E31, E35, E38, E40-E45 and E48-E74, wherein EtOH is used as solvent in step 5.

[0330] E76. A method according to any one of embodiments E30-E31, E35, E38, E40-E45 and E48-E75, wherein the hydrogenation reaction in step 5 is carried out using a palladium catalyst at a temperature in the range of about 20°C to about 100°C, such as about 50°C to about 100°C, such as about 60°C to about 80°C, such as about 65°C, about 67°C, or about 68°C, about 69°C, about 70°C, about 71°C, about 72°C, about 73°C, about 75°C or about 77°C.

[0331] E77. A method according to any one of embodiments E30-E31, E35, E38, E40-E45 and E48-E76, wherein the hydrogenation reaction in step 5 is carried out using a palladium catalyst at a pressure in the range of about 2 bar to about 10 bar, such as about 3 bar to 6 bar, such as about 3 bar to about 5 bar, such as about 3.5 bar, or about 4 bar, or about 4.5 bar.

[0332] E78. The method according to any one of embodiments E42-E45 and E48-E77, wherein step 6 comprises reacting compound (Ib) with BCl 3 The reaction is carried out to obtain compound (I) or a salt thereof.

[0333] E79. The method according to any one of embodiments E42-E45 and E48-E78, wherein step 6 comprises reacting compound (Ib) in the form of a free base with BCl 3 The reaction is carried out to obtain compound (I) or a salt thereof.

[0334] E80. The method according to any one of embodiments E42-E45 and E48-E79, wherein step 6 comprises reacting a salt of compound (Ib) with a base to obtain compound (Ib) as a free base, followed by reacting compound (Ib) with BCl 3 The reaction is carried out to obtain compound (I) or a salt thereof.

[0335] E81. The method according to any one of embodiments E42-E45 and E48-E80, wherein step 6 comprises reacting a salt of compound (Ib) with Na 2 CO 3 , K 2 CO 3 or aqueous ammonia to obtain compound (Ib) as a free base, and then compound (Ib) is reacted with BCl 3 The reaction is carried out to obtain compound (I) or a salt thereof.

[0336] E82. The method according to any one of embodiments E42-E45 and E48-E81, wherein step 6 comprises reacting the (-)-O,O′-di-p-methylbenzoyl-L-tartrate (L-DTTA) salt of compound (Ib) with a base to obtain the free base of compound (Ib), followed by reacting compound (Ib) with BCl 3 Reaction to obtain Compound (I) or a salt thereof, such as HCl salt of Compound (I).

[0337] E83. The compound according to embodiment E23, which is in the form of a hydrochloride salt as depicted below

[0338]

[0339] E84. Use of a compound according to any one of embodiments E23 and E83 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0340] E85. A method for producing a compound (I) having the following formula

[0341]

[0342] The compound is prepared from compound (Ib) having the following formula:

[0343]

[0344] Wherein compound (Ib) is prepared by a method comprising the following steps:

[0345] Step 0)

[0346] Sub-step (S1) reacts compound (a6i) with tert-butyl 2-bromoacetate and zinc to form a mixture, followed by

[0347] The mixture from substep (S1) is treated with acetic acid, followed by

[0348] reacting the mixture with 3-chloropropane-1-amine hydrochloride to provide compound (a2i);

[0349] Followed by

[0350] Step 1)

[0351] Sub-step (ii) reducing the compound (a2i) obtained in sub-step (S1) to obtain compound (a2ii), followed by

[0352] Sub-step (iii) resolving compound (a2ii) using L-tartaric acid to provide compound (A2-hemi-L-tartrate);

[0353] Proceed according to the following reaction scheme:

[0354]

[0355] E86. The method according to embodiment E85, wherein compound (a6i) or a salt thereof is prepared by a method comprising the step of reacting compound (a5i) or a salt thereof with a chlorinating agent.

[0356]

[0357] E87. The method according to embodiment E86, wherein the chlorinating agent is sulfuryl chloride.

[0358] E88. The method according to any one of embodiments E85-E87, wherein compound (a2i) is isolated before starting step 1 sub-step (ii).

[0359] E89. The method according to any one of embodiments E85-E88, which is further defined by any one of embodiments E5-E7, E12-E16, E19-E22, E26, E30-E45 and E48-E82.

[0360] E90. The method according to any one of embodiments E85-E89, wherein compound (A3) is prepared by a method comprising the following steps:

[0361] 2) According to the following reaction scheme b), the compound (A2-semi-L-tartrate) is reacted with propionaldehyde in the presence of a reducing agent,

[0362] To provide compound (A3)

[0363] Solution b)

[0364]

[0365] All documents (including publications, patent applications, and patents) cited herein are hereby incorporated by reference in their entirety and to the same extent as if each document were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein (to the maximum extent permitted by law).

[0366] Headings and sub-headings are used herein for convenience only and should not be construed as limiting the invention in any way.

[0367] Unless stated otherwise or clearly contradicted by context, descriptions of any aspect or aspects of the invention herein using terminology such as “comprising,” “having,” “including,” or “containing” in reference to one or more elements are intended to provide support for the similar aspect or aspects of the invention “consisting of,” “consisting essentially of,” or “consisting essentially of,” the specified one or more elements (e.g., a composition described herein as comprising a specified element is to be understood to also describe a composition consisting of that element, unless stated otherwise or clearly contradicted by context).

[0368] Any and all examples or exemplary language (including "for example," "such as," "like," "such as," and "according to") used in this specification are intended merely to better illuminate the invention and do not pose a limitation on the scope of the invention unless otherwise indicated.

[0369] It should be understood that the various aspects, embodiments, implementations and features of the invention mentioned herein may be claimed individually or in any combination.

[0370] This invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law.

[0371] Project List

[0372] In the following bullet list, some further embodiments of the present invention are disclosed. The first embodiment is denoted as EE1, the second embodiment is denoted as EE2, and so on.

[0373] EE1. A method for producing a compound (Ib) having the following formula

[0374]

[0375] The method comprises the following steps:

[0376] Step 0)

[0377] Sub-step (i) reacting compound (A1) with 3-chloropropane-1-amine to obtain compound (a2i); or

[0378] Sub-step (S1) reacts compound (a6i) with tert-butyl 2-bromoacetate and zinc to form a mixture, followed by

[0379] The mixture from step (S1) is treated with acetic acid, followed by

[0380] reacting the mixture with 3-chloropropane-1-amine hydrochloride to provide compound (a2i);

[0381] Followed by

[0382] Step 1)

[0383] Sub-step (ii) reducing the compound (a2i) obtained in step (i) or sub-step (S1) to obtain compound (a2ii), followed by

[0384] Sub-step (iii) resolving compound (a2ii) using L-tartaric acid to provide compound (A2-hemi-L-tartrate); or

[0385] Sub-step (i) or sub-step (S1) is followed by sub-step (iv) comprising the following steps: hydrogenating compound (a2i) with a chiral catalyst in the presence of hydrogen and a solvent to provide compound (A2); according to the following reaction scheme:

[0386]

[0387] EE2. The method according to Example E1, wherein compound (a6i) is prepared by a method comprising the step of reacting compound (a5i) with a chlorinating agent

[0388]

[0389] EE3. The method according to embodiment EE2, wherein the chlorinating agent is sulfuryl chloride.

[0390] EE4. The method according to any one of embodiments EE1 to EE3, wherein the reduction in step 1 substep (ii) occurs in the presence of a reducing agent.

[0391] EE5. The method according to any one of embodiments EE1 to EE4, wherein the reducing agent is selected from NaBH 3 CN, sodium triacetoxyborohydride (STAB), borane such as 5-ethyl-2-methylpyridine borane (PEMB), and NaBH 4 .

[0392] EE6. The method according to any one of embodiments EE1 to EE5, wherein the reduction in step 1 substep (ii) occurs by using a platinum catalyst, preferably platinum on carbon.

[0393] EE7. The method according to embodiments EE1 to EE3, wherein the chiral catalyst in step 1 sub-step (iv) is selected from (2S)-1-[(1S)-1-[bis(1,1-dimethylethyl)phosphino]ethyl]-2-(diphenylphosphino)ferrocene and bis(2,5-norbornadiene)rhodium(I) tetrafluoroborate.

[0394] EE8. The method according to claims EE1 to EE3 and EE7, wherein the solvent in step 1 sub-step (iv) is 2,2,2-trifluoroethanol.

[0395] EE9. A compound having the following formula (A2)

[0396]

[0397] or a salt thereof.

[0398] EE10. The compound according to embodiment E8 in the form of a hemi-L-tartrate salt as depicted below

[0399]

[0400] EE11. Use of the compound according to any one of embodiments EE9 and EE10 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0401] EE12. The method according to any one of embodiments EE1 to EE8, wherein compound (Ib) is prepared by a method comprising the following steps:

[0402] 2) according to the following reaction scheme a) or b), compound (A2) or compound (A2-semi-L-tartrate) is reacted with propionaldehyde in the presence of a reducing agent,

[0403] To provide compound (A3)

[0404] Solution a)

[0405]

[0406] Solution b)

[0407]

[0408] EE13. The method according to embodiment EE12, wherein compound (A3) is prepared by reacting compound (A2-hemi-L-tartrate) with propionaldehyde in the presence of a reducing agent.

[0409] EE14. The method according to embodiment EE13, wherein the reducing agent is selected from NaBH 3 CN, sodium triacetoxyborohydride (STAB), borane, preferably 5-ethyl-2-methylpyridine borane (PEMB), or hydrogenation with a platinum catalyst, preferably platinum on carbon, and hydrogen.

[0410] EE15. The method according to any one of embodiments EE12 to EE14, wherein the reaction occurs in a solvent selected from, for example, tetrahydrofuran (THF), isopropanol (IPA), or MeOH.

[0411] EE16. A compound having the following formula (A3)

[0412]

[0413] or a salt thereof.

[0414] EE17. Use of the compound according to embodiment EE16 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0415] EE18. The method according to embodiments E1 to EE8 and EE12 to EE15, wherein compound (Ib) is prepared by a method comprising the following steps:

[0416] 3) Compound (A3) is reacted with a strong base according to the following reaction scheme to provide compound (A4)

[0417]

[0418] Optionally, compound (A4) is then isolated as the hemi-oxalate salt as depicted below

[0419]

[0420] EE19. The method according to embodiment EE16, wherein the strong base is sodium bis(trimethylsilyl)amide (NaHMDS).

[0421] EE20. A method according to any one of embodiments EE16 to EE17, wherein the reaction between compound (A3) and the base occurs at a temperature in the range of -20°C to -5°C, such as in the range of -15°C to -5°C, or such as at a temperature of about -10°C.

[0422] EE21. The method according to any one of embodiments EE16 to EE18, wherein the compound (A4) is mixed with oxalic acid and isolated as the hemi-oxalate salt.

[0423] EE22. A compound having the following formula (A4)

[0424]

[0425] or a salt thereof.

[0426] EE23. The compound according to embodiment EE22, which is in the form of a hemi-oxalate salt as depicted below

[0427]

[0428] EE24. Use of a compound according to any one of embodiments EE22 to EE23 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0429] EE25. The method according to embodiments EE1 to EE8, EE12 to EE15, EE18 to EE21, wherein compound (Ib) is prepared by a method comprising the following steps:

[0430] 4) Intramolecular Friedel-Crafts acylation of compound (A4) was performed according to the following reaction scheme to provide compound (A5)

[0431]

[0432] Optionally, a subsequent step of isolating compound (A5) as a tosylate salt (A5-tosylate) is performed.

[0433]

[0434] EE26. A compound having the following formula (A5)

[0435]

[0436] or a salt thereof.

[0437] EE27. The compound according to embodiment EE26, which is in the form of a tosylate salt as depicted below

[0438]

[0439] EE28. Use of a compound according to any one of embodiments EE26 to EE27 in a process for preparing a compound of formula (I) or a compound of formula (Ib).

[0440] EE29. The method according to embodiments EE1 to EE8, EE12 to EE15, EE18 to EE21, and EE25, wherein compound (Ib) is prepared by a method comprising the following steps:

[0441] 5) Reducing compound (A5) or a salt thereof according to the following reaction scheme to obtain compound (Ib) or a salt thereof

[0442]

[0443] EE30. The method according to embodiment EE29, wherein the reduction occurs by using a palladium catalyst.

[0444] EE31. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0445] According to step 0) of any one of embodiments EE1 to EE3; followed by step 1) of any one of embodiments EE1 and EE4 to EE8; followed by

[0446] Step 2) according to any one of embodiments EE12 to EE15.

[0447] EE32. The method according to any one of embodiments EE1 to EE8, wherein compound (Ib) is prepared by a method comprising the following steps:

[0448] According to step 2) of any one of embodiments EE12 to EE15; followed by

[0449] According to step 3) of any one of embodiments EE18 to EE21.

[0450] EE33. The method according to any one of embodiments EE1 to EE8 and EE12 to EE15, wherein compound (Ib) is prepared by a method comprising the following steps:

[0451] According to step 3 of any one of embodiments EE18-21); followed by

[0452] According to step 4 as described in embodiment EE25).

[0453] EE34. The method according to any one of embodiments EE1 to EE8, wherein compound (Ib) is prepared by a method comprising the following steps:

[0454] According to step 4 described in any one of embodiments EE25); followed by

[0455] Step 5) according to any one of embodiments EE29 to EE30.

[0456] EE35. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0457] According to step 0) of any one of embodiments EE1 to EE3; followed by step 1) of any one of embodiments EE1 and EE4 to EE8; followed by

[0458] According to step 2) of any one of embodiments EE12 to EE15; followed by

[0459] Step 3) according to any one of embodiments EE18-EE21.

[0460] EE36. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0461] According to step 2) of any one of embodiments EE12 to EE15; followed by

[0462] Step 3) according to any one of embodiments EE18-EE21; followed by step 4) according to embodiment EE25.

[0463] EE37. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0464] According to step 3) of any one of embodiments EE18-EE21; followed by step 4) according to embodiment EE25; followed by

[0465] Step 5) according to any one of embodiments EE29 to EE30.

[0466] EE38. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0467] According to step 1) of any one of embodiments EE1 and EE4 to EE8; followed by

[0468] According to step 2) of any one of embodiments EE12 to EE15; followed by

[0469] Step 3) according to any one of embodiments EE18-EE21; followed by step 4) according to any one of embodiments EE25.

[0470] EE39. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0471] According to step 2) of any one of embodiments EE12 to EE15; followed by

[0472] According to step 3) of any one of embodiments EE18-EE21; followed by step 4) according to embodiment EE25; followed by

[0473] Step 5) according to any one of embodiments EE29 to EE30.

[0474] EE40. The method according to embodiment 1, wherein compound (Ib) is prepared by a method comprising the following steps:

[0475] According to step 0) of any one of embodiments EE1 to EE3; followed by step 1) of any one of embodiments EE1 and EE4 to EE8; followed by

[0476] According to step 2) of any one of embodiments EE12 to EE15; followed by

[0477] According to step 3) of any one of embodiments EE18-EE21; followed by step 4) according to embodiment EE25; followed by

[0478] Step 5) according to any one of embodiments EE29 to EE30.

[0479] EE41. A method for producing compound (I) according to any one of embodiments EE1-EE8, EE12-EE15, EE18-EE21, EE25, EE29-EE30 and EE32 to EE40, wherein compound (I) is prepared from compound (Ib) by the following steps.

[0480] EE42. The method for making compound (Ib) according to any one of embodiments EE1-EE8, EE12-EE15, EE18-EE21, EE25, EE29-EE30 and EE32 to EE40, wherein the method is an ex vivo chemical method.

[0481] EE43. A method for making compound (Ib) according to any one of embodiments EE1-EE8, EE12-EE15, EE18-EE21, EE25, EE29-EE30 and EE31 to EE42, wherein the method is further defined in any one of embodiments E48 to E82 and E85-E90.

[0482] EE44. A method for producing a compound having the following formula (Ib)

[0483]

[0484] Wherein compound (Ib) is prepared by a method comprising the following steps:

[0485] Step 0)

[0486] Sub-step (S1) reacts compound (a6i) with tert-butyl 2-bromoacetate and zinc to form a mixture, followed by

[0487] The mixture from substep (S1) is treated with acetic acid, followed by

[0488] reacting the mixture with 3-chloropropane-1-amine hydrochloride to provide compound (a2i);

[0489] Followed by

[0490] Step 1)

[0491] Sub-step (ii) reducing the compound (a2i) obtained in sub-step (S1) to obtain compound (a2ii), followed by

[0492] Sub-step (iii) resolving compound (a2ii) using L-tartaric acid to provide compound (A2-hemi-L-tartrate);

[0493] Proceed according to the following reaction scheme:

[0494]

[0495] EE45. The method according to embodiment EE44, wherein compound (a6i) or a salt thereof is prepared by a method comprising the step of reacting compound (a5i) or a salt thereof with a chlorinating agent.

[0496]

[0497] EE46. The method according to embodiment EE45, wherein the chlorinating agent is sulfuryl chloride.

[0498] EE47. The method according to any one of embodiments EE44-E46, wherein compound (a2i) is isolated before starting step 1 sub-step (ii).

[0499] EE48. The method according to any one of embodiments EE44-EE47, which is further defined by any one of embodiments E5-E7, E12-E16, E19-E22, E26, E30-E45 and E48-E82.

[0500] EE49. The method according to any one of embodiments EE44-EE48, wherein compound (A3) is prepared by a method comprising the following steps:

[0501] 2) According to the following reaction scheme b), compound (A2-hemi-L-tartrate) is reacted with propionaldehyde in the presence of a reducing agent to provide compound (A3)

[0502] Solution b)

[0503]

[0504] Experimental Section

[0505] abbreviation:

[0506] DCM: dichloromethane

[0507] DEA: Diethylamine

[0508] ee: enantiomeric excess

[0509] EtOAc: ethyl acetate

[0510] IPA: Isopropyl alcohol

[0511] iPrOAc: isopropyl acetate

[0512] iPrOH: isopropyl alcohol

[0513] Me-THF: 2-methyltetrahydrofuran

[0514] NaHMDS: Sodium bis(trimethylsilyl)amide

[0515] Pd / C: Palladium on carbon

[0516] PEMB: 5-ethyl-2-methylpyridine borane

[0517] STAB: Sodium triacetoxyborohydride

[0518] TFA: trifluoroacetic acid

[0519] THF: Tetrahydrofuran

[0520] Me-THF: 2-methyltetrahydrofuran

[0521] TsOH: p-Toluenesulfonic acid

[0522] v / v: volume ratio

[0523] w / w: weight ratio

[0524] NMR methods

[0525] QNMR (600MHz):

[0526] 1) Relaxation delay 40 seconds

[0527] 2) Collection time: 3.76 seconds

[0528] 3) Time domain 64k

[0529] 4) Size 32k

[0530] 5) Virtual Scan 4

[0531] 6) Scan 8

[0532] 7) Pulse 30deg LC-MS and HPLC methods

[0533] Analytical LC-MS data were obtained using the following identified method.

[0534] LC-MS Methods: LC-MS was run on a Waters Aquity UPLC-MS system consisting of a column manager, binary solvent manager, sample organizer, PDA detector (operating at 254 nM), ELS detector, and TQ-MS equipped with an APPI source operating in positive ion mode.

[0535] LC-conditions: Column was Acquity UPLC BEH C18 1.7 μm; 2.1 x 150 mm, operated at 60°C with a binary gradient of 0.6 mL / min consisting of water + 0.05% trifluoroacetic acid (A) and acetonitrile / water (95:5) + 0.05% trifluoroacetic acid.

[0536] Gradient(Linear);

[0537] 0.00min 10% B

[0538] 3.00min 100% B

[0539] 3.60min 10% B

[0540] Total running time: 3.6 minutes

[0541] Chiral HPLC Method: Chiral HPLC was run on a Merck Hitachi 7000 series HPLC consisting of: pump, interface, programmable autosampler, column oven, and UV detector (operated at 220 nm). The column was Chiralpak AD-H 5 μm; 4.6 x 250 mm, operated at 30°C with an eluent (consisting of 90 / 10 / 0.1 hexanes / IPA / DEA v / v) flow rate of 1.0 mL / min and a total run time of 20 minutes.

[0542] Example 1: Preparation of compounds (a2i), (a2ii) and (A2-semi-L-tartrate) (step 0 sub-step (i) followed by Perform step 1 sub-steps (ii) and (iii))

[0543] A mixture of 3-chloropropane-1-amine hydrochloride (24.9 g, 192 mmol), compound (A1) (20.0 g, 63.9 mmol), zinc chloride in Me-THF (1.7 ml, 3.20 mmol, 1.9 M), sodium acetate (17.3 g, 211 mmol) and sodium sulfate (4.54 g, 32.0 mmol) in Me-THF (150 mL) was stirred overnight.

[0544] Then a solution of sodium cyanoborohydride (5.22 g, 83 mmol) in Me-THF (50 mL) was slowly added at room temperature, and the mixture was stirred at 40° C. for 4 hours. The mixture was cooled to room temperature and slowly added to saturated NH 4 Cl aqueous solution (100 mL) and water (100 mL) were stirred. The mixture was stirred at room temperature for 15 minutes. The organic phase was separated and washed with saturated NH 4 The mixture was washed with a mixture of aqueous Cl solution and water (100 mL, 1:1 v / v), and then with saturated NaHCO 3The organic phase was washed with brine (100 mL) and purified by MgSO 4 Dried, filtered and co-evaporated with MeOH for several rounds to dryness to give crude compound (a2ii) (27.7 g) as an oil.

[0545] Under reflux, with stirring, add a solution of L-tartaric acid (5.32 g, 35.5 mmol) in MeOH (43 mL) to a solution of crude compound (a2ii) in MeOH (150 mL). Allow the mixture to be slowly cooled to room temperature with stirring overnight, and seeding (about 20 mg) just below reflux. The obtained suspension is filtered, and the filter cake is washed with MeOH (20 mL) and dried in a vacuum oven at 40 ° C, to produce a solid compound (A2-half-L-tartrate) (11.3 g, 38%), according to chiral HPLC analysis, it has a S:R ratio of compound (A2) of 1: 161 (99.4% ee).

[0546] LC-MS: RT = 2.22 min, [M+H] + =390.0m / z.

[0547] 1 H NMR (600 MHz, DMSO-d 6 )δ7.03(s,1H),6.95(s,1H),6.04(dd,J=1.0,1.0Hz,2H),4.12(s,2H,L-tartaric acid ),3.66(t,J=6.5Hz,2H),3.21(quint,J=8.0Hz,1H),2.91(dd,J=6.0,13.5H z,1H),2.75(t,J=7.0Hz,2H),2.62(dd,J=8.5,13.5Hz,1H),2.31(dd,J=7.0 ,15.5Hz,1H),2.26(dd,J=7.0,15.5Hz,1H),1.82-1.86(m,2H),1.36(s,9H).

[0548] Example 2: Preparation of compound (A3) (Step 2).

[0549] A mixture of compound (A2-semi-L-tartrate) (400 mg, 0.43 mmol), propionaldehyde (80 μL, 1.12 mol), acetic acid (49 μL, 0.86 mmol), and THF (4.0 mL) was stirred for 30 minutes. STAB (182 mg, 0.86 mmol) was then added. The reaction mixture was stirred at room temperature for 3.5 hours. Saturated NaHCO 3Aqueous solution (4 mL) was added and the mixture was extracted with toluene. The organic extract was purified by MgSO 4 Dried, filtered and evaporated to dryness to give crude Compound (A3) (167 mg, 90%) as a solid.

[0550] LC-MS: RT = 2.46 min, [M+H] + =432.3m / z.

[0551] 1 H NMR (600 MHz, CDCl 3 )δ6.80(s,1H),6.62(s,1H),5.94(s,2H),3.49-3.55(m,2H),3.35-3.39(m, 1H),2.90(dd,J=3.5,13.5Hz,1H),2.61-2.63(m,2H),2.52(dd,J=9.0,13.5 Hz,1H),2.36-2.45(m,3H),2.16(dd,J=5.5,14.5Hz,1H),1.86-1.92(m,1H) ,1.76-1.83(m,1H),1.39-1.49(m,2H),1.41(s,9H),0.86(t,J=7.5Hz,3H).

[0552] Example 3: Preparation of compound (A4) (Step 3).

[0553] At -10 ℃, in the time period of 7.5 minutes, to the solution of compound (A3) (40.0g, 92.5mmol) and toluene (311mL), add the NaHMDS solution (93.2mL, 185mmol, 2M) in THF. Observe that temperature has slight rise. The reaction mixture is stirred at -10 ℃ for 50 minutes. Then the temperature is raised to 5 ℃ and kept overnight. Then the reaction mixture is allowed to reach room temperature, and the NaCl aqueous solution (160g, 5%w / w) is added in the time period of 5 minutes. The organic phase is separated and evaporated to dryness in a vacuum. The residue is stripped with acetone (200mL), and the residue is mixed with acetone and oxalic acid (8.30g, 92.2mmol) and stirred at room temperature overnight. Then the mixture is cooled on an ice bath for 1 hour and filtered. The filter cake was washed twice with cold acetone (2 x 50 mL), crushed and dried in vacuo at 50°C to give compound (A4-hemi-oxalate) (35.0 g, 78%) as a powder, which was prepared as 1 H NMR analysis confirmed the presence of only the cis isomer.

[0554] LC-MS: RT = 0.61 min, [M+H] + =396.3m / z.

[0555] 1 H NMR (600 MHz, DMSO-d 6 )δ7.07(s,1H),7.03(s,1H),6.06(s,2H),3.73(br s,1H),2.99-3.16(m,2H),2.73-2.90(m,4H),2.43(br s,1H),1.88-1.96(m,1H),1.60-1.80(m,3H),1.45-1.56(m,2H),1.35(s,9H),0.81(t,J=7.5Hz,3H).

[0556] Example 4: Preparation of compound (A5) (Step 4)

[0557] Free base of compound (A4-hemi-oxalate):

[0558] A mixture of compound (A4-hemi-oxalate) (1000 g, 2.06 mol), heptane (8 L), water (6 L) and aqueous ammonia (500 mL, 6.76 mol, 25% w / w) was stirred at 35-45° C. for 4 hours. The organic phase was separated and concentrated to 1-2 liters by distillation at >95° C. Chlorobenzene (1.0 L) was then added, and the mixture was concentrated to 1.5-2.0 liters by distillation in vacuo to produce a solution of compound (A4) as a free base.

[0559] Formation of compound (A5):

[0560] Trifluoroacetic acid (50.0 mL, 650 mmol) was added to the P at 15°C-30°C over a period of 5-15 minutes. 2 O 5 (30 g, 211 mmol) and chlorobenzene (200 mL) were added to a stirred mixture of 1,2-dihydro-1,4-dihydro-2-nitropropene (2,4 ...

[0561] A solution of compound (A4) in chlorobenzene as a free base (see above, corresponding to 50 g of compound (A4-semi-oxalate) (103 mmol)) was then added at 25°C-45°C over a period of 10-30 minutes. The resulting mixture was stirred at 35°C-40°C for 3 hours, and then at room temperature overnight. IPA (125 mL) was added to the reaction mixture at room temperature, and the mixture was stirred at 40°C-45°C for 2 hours, and then at room temperature overnight. At 5°C-10°C, the mixture was added to a stirred mixture of aqueous ammonia (150 mL, 2.00 mol, 25% w / w) and water (1.0 L) over a period of 5-10 minutes. The mixture was stirred at 35°C-45°C for 10 minutes. The organic phase was separated, and the aqueous phase was extracted with chlorobenzene (100 mL). TsOH-H was added to the stirred combined organic phase. 2 A solution of 1,4-dihydro-2-nitropropene (23.6 g, 124 mmol) in IPA (150 mL) was added. The mixture was concentrated to a volume of about 50 mL in a rotary evaporator at 50°C-70°C in a vacuum. IPA (100 mL) was added, and the mixture was concentrated to about 50 mL in a rotary evaporator in a vacuum again. IPA (125 mL) was added and the mixture was stirred at room temperature to allow precipitation. The formed suspension was cooled to 5°C and filtered. The filter cake was washed twice with cold IPA (2x 20 mL, 5°C) and dried in a vacuum oven at 50°C to produce a powdered compound (A5-toluenesulfonate) (35.6 g, 70%).

[0562] LC-MS: RT = 1.62 min, [M+H] + =322.2m / z.

[0563] 1 H NMR (600 MHz, DMSO-d 6 )δ9.65(br s,1H),7.46-7.48(m,2H),7.45(s,1H),7.09-7.11(m,2H),6.23(d,J=5.5Hz,1H),6.21(d, J=5.5Hz,1H),3.67-3.74(m,1H),3.56(dd,J=4.5,16Hz,2H),3.31-3.39(m,1H),3.06-3.1 4(m,1H),2.93-3.03(m,1H),2.83-2.93(m,2H),2.27(s,3H),2.18-2.24(m,1H),1.91-1.9 8(m,1H),1.70-1.84(m,2H),1.61-1.70(m,1H),1.41-1.50(m,1H),0.96(t,J=7.5Hz,3H).

[0564] Example 5: Preparation of Compound (Ib) (Step 5)

[0565] A mixture of compound (A5-tosylate) (5.00 g, 10.1 mmol), 5% Pd / C (561 mg, 0.101 mmol, Johnson Matthey 424) and EtOH (50 mL) was hydrogenated at 4 bar hydrogen and 70° C. for 48 hours. The reaction mixture was filtered through Arbocell BC200, and the filtrate was co-evaporated with toluene several times. The resulting solution was washed with dilute aqueous ammonia (10% w / w), then with brine, and filtered through MgSO 4 Dried, filtered and evaporated to dryness to give Compound (Ib) (2.59 g) as a solid.

[0566] LC-MS: RT = 1.95 min, [M+H] + =274.3m / z.

[0567] 1 H NMR (600 MHz, CDCl 3 )δ6.63(d,J=8.0Hz,1H),6.59(d,J=8.0Hz,1H),5.92(d,J=1.5Hz,1H),5.89(d,J=1.5Hz,1H),3.15(dd,J=5 .0,16.0Hz,1H),2.97-3.00(m,1H),2.82(dd,J=5.0,17.0Hz,1H),2.73(ddd,J=5.5,10.5,13.5Hz,1H),2.5 6(dd,J=11.0,15.5Hz,1H),2.49(ddd,J=5.5,10.5,13.5Hz,1H),2.21-2.30(m,1H),2.18(dt,J=5.0,10.5H z,1H),1.87-1.92(m,1H),1.58-1.72(m,2H),1.42-1.58(m,1H),1.06-1.15(m,1H),0.89(t,J=7.5Hz,3H).

[0568] Example 6: Preparation of Compound (I) from Compound (Ib) (Step 6)

[0569] A 2L three-necked flask with a mechanical overhead stirrer was charged with (-)-O,O'-di-p-methylbenzoyl-L-tartrate (L-DTTA) salt (242g, 367mmol), toluene (1250mL), water (375mL) and 25% aqueous ammonia (100mL, 1340mmol) of compound (Ib). The mixture was stirred at 20°C-25°C for 50 minutes, and then the phases were separated. The organic phase was washed with a mixture of 25% aqueous ammonia (35mL, 470mmol) of water (170mL). The separated organic phase was concentrated to near dryness at 50°C under vacuum. The residue was continuously concentrated three times to near dryness at 50°C under vacuum with toluene (3x 250mL). The residue was dissolved and transferred to a 4L three-necked flask equipped with toluene (1200mL). The solution was cooled to 4°C and BCl in toluene was added over a period of 25 minutes. 3 The mixture was stirred at 0-5 ° C for 3 hours. After stirring for another 1.8 hours at 0-5 ° C, the reaction mixture was quenched by adding methanol (500 mL) within 20 minutes. The resulting mixture was heated at 55 ° C overnight, and then heated to reflux, wherein 500 mL of solvent was distilled off. Methanol (500 mL) was added, and the mixture was heated to reflux, wherein 500 mL of solvent was distilled off. IPA (500 mL) was added, and the mixture was heated to reflux, wherein 500 mL of solvent was distilled off. IPA (500 mL) was added, and the mixture was heated to reflux, wherein 500 mL of solvent was distilled off. IPA (1200 mL) was added, and the mixture was heated to 75 ° C for 1.5 hours. The suspension was cooled to 20 ° C in 1.5 hours, and then the product was filtered out. The filter cake was washed twice with IPA / toluene (1: 1, 2x 200 mL). Drying under vacuum at 50 ° C provides the HCl salt (105 g, 96%) of compound (I) as a solid.

[0570] 1 H NMR (600 MHz, DMSO-d 6)δ6.53(d,J=8.0Hz,1H),6.37(d,J=8.0Hz,1H),3.01(dd,J=4.5,15.0Hz,1H),2.89(app d,J=11.0Hz,1H),2.79(dd,J=5.0,17.5Hz,1H),2.65-2.70(m,1H),2.36( dd,J=11.0,15.5Hz,1H),2.25-2.30(m,1H),2.12(dt,J=2.5,12.0Hz,1H), 1.99-2.05(m,2H),1.79-1.84(m,1H),1.58-1.63(m,1H),1.49-1.57(m,1H ), 1.35-1.47 (m, 3H), 1.05 (dq, J = 4.0, 13.0Hz, 1H), 0.84 (t, J = 7.5Hz, 3H).

[0571] Example 7: Preparation of Compound (A2-semi-L-tartrate) from Compound (a2i) (Step 1 using Pt catalyst) Step (ii), and step 1 sub-step iii)

[0572] A mixture of compound (a2i) (12.4 g, 32.0 mmol) and platinum carbon (Johnson Matthey 128M type; 4.88% Pt; 52.6% w / w water; 2.16 g, 0.256 mmol) in Me-THF (31 mL) was hydrogenated at 60 ° C and 4 bar hydrogen for 24 hours. The reaction mixture was filtered and evaporated to dryness to produce crude compound (a2ii). A solution of L-tartaric acid (2.40 g, 16.0 mmol) in MeOH (20 mL) was slowly added to the crude compound (a2ii) in MeOH (67 mL) under reflux with stirring. The mixture was allowed to slowly cool to room temperature with stirring overnight, and seeded at about 62 ° C (about 20 mg pure compound (A2-half-L-tartrate)). The obtained suspension was filtered, and the filter cake was washed with MeOH (10 mL) and dried in a vacuum oven at 40 °C to give Compound (A2-hemi-L-tartrate) (4.90 g, 33%) as a white solid with 99.2% enantiomeric excess of compound (A2) according to chiral HPLC analysis.

[0573] Example 8: Preparation of Compound (A1) from Compound (a6i) (Sub-step 0')

[0574] Methanesulfonic acid (83 μ L, 1.28 mmol) is added to the zinc powder (Umicore) (2.84 g, 43.5 mmol) of vigorous stirring in THF (15.0 mL). The mixture is heated under reflux for 30 minutes. Then a solution of compound (a6i) (5.00 g, 25.6 mmol) in THF (15.0 mL) is added, followed by dropwise addition of 2- bromoacetic acid tert-butyl ester (6.48 g, 33.2 mmol) under reflux in a time period of 1 hour and 40 minutes. The mixture is stirred under reflux for 1 hour, heating is removed, and the stirred reaction mixture is cooled to room temperature overnight. The reaction mixture is added to the HCl aqueous solution (38 mL, 76 mmol, 2.0 M) at 0 ° C with stirring. The resulting mixture is concentrated under vacuum to remove most of THF, and then cooled in an ice-water bath with vigorous stirring, and seeded with a pure sample of compound (A1).

[0575] The resulting suspension was filtered cold (ca. 5° C.) and the filter cake was washed with a 10:1 water:THF mixture and dried in a vacuum oven at 40° C. overnight to yield Compound (A1) (7.72 g, 97%) as a light yellow solid.

[0576] LC-MS (method: 555) RT = 2.84 and 3.41 min (the two peaks are keto and enol tautomers of compound (A1))

[0577] 1 H NMR (600 MHz, DMSO-d 6 )δ7.07(s,1H),6.89(s,1H),6.06(s,2H),3.90(s,2H),3.53(s,2H),1.41(s,9H).

[0578] Example 9: Preparation of Compound (a2i) from Compound (a6i) (Step 0 Sub-step S1)

[0579] A mixture of zinc powder (Umicore) (10.0 g, 153 mmol) and methanesulfonic acid (332 μL, 5.11 mmol) in THF (60 mL) was heated at reflux with stirring for 30 min.

[0580] Add a solution of compound (a6i) (20.0 g, 102 mmol) in THF (60 mL). Then slowly add tert-butyl 2-bromoacetate (25.9 g, 133 mmol) under reflux over a period of 2 hours. Stir the reaction mixture under reflux for 2 hours. Cool the reaction mixture to room temperature.

[0581] The reaction mixture is filtered out from excessive zinc and cooled in an ice-water bath. Acetic acid (7.6mL, 133mmol) is then slowly added with stirring. The mixture is co-evaporated several times with MeOH to remove THF via THF-MeOH azeotropic. This produces a suspension, to which a solution of 3-chloropropane-1-amine hydrochloride (33.2g, 256mmol) in MeOH (50mL) is added. The mixture is stirred at room temperature overnight. The mixture is filtered, and the filter cake is washed with a small amount of MeOH, and is dried at 40 ° C in a vacuum oven to produce a white solid compound (a2i) (32.0g, 81%).

[0582] LC-MS (method: 555) RT = 2.84 and 3.41 min (LC-MS analysis showed that the two peaks were keto and enol tautomers of compound (A1), which was due to the hydrolysis of compound (a2i) to compound (A1)).

[0583] 1 H NMR (600 MHz, DMSO-d 6 )δ8.57(t,J=6.5Hz,1H),7.10(s,1H),6.89(s,1H),6.08(s,2H),3.85(s,1H),3.67(t, J=6.5Hz,2H),3.58(s,2H),3.33(q,J=6.5Hz,2H),1.95(q,J=6.5Hz,2H),1.36(s,9H). Example 10: Preparation of Compound (a6i) from Compound (a5i)

[0584] At 0 ° C, sulfuryl chloride (17.4 ml, 214 mmol) was added to a mixture of compound (a5i) (30.0 g, 186 mmol) and n-heptane (200 mL) under vigorous stirring. Cooling was removed, and the mixture was allowed to warm to room temperature with vigorous stirring. The mixture was stirred at room temperature for 4 hours. The formed suspension was filtered, and the precipitate was washed with heptane, and dried in a vacuum at 40 ° C to provide compound (a6i) (33.4 g, 92%) as a white solid.

[0585] LC-MS (method: 555) RT = 2.28 min, [M+H] + =195.1m / z.

[0586] 1 H NMR (600 MHz, CDCl 3 )δ6.95(s,1H),6.88(s,1H),6.02(s,2H),3.74(s,2H).

[0587] Example 11: Large-Scale Preparation of Compound A4-HCl from Compound A2-Hemi-L-Tartrate (Step 2 and Step 3)

[0588] To a 10°C cold slurry containing compound (A2-hemi-l-tartrate) (750 g, 805.9 mmol, 1 eq) and sodium triacetoxyborohydride (597.8 g, 2820 mmol, 3.5 eq) in THF (3750 mL, 5 vol) was added a cold (10°C) solution of propionaldehyde (121.7 g, 150.2 mL, 2100 mmol, 2.6 eq) in THF (1500 mL, 2 vol) over the course of 30 min. Subsequently, glacial acetic acid (169.4 g, 161.5 mL, 2820 mmol, 3.5 eq) was added at 21°C over the course of 5 min and the reaction mixture was stirred at 23°C overnight. Then, 10% of the volume was distilled off under vacuum at 25°C before water (2250 mL, 3 vol) was added and the solution was stirred at 22°C for 1 hour. Next, toluene (2250mL, 3 volumes) was added, followed by 25% aqueous ammonia (880mL, 1176mmol, 14.6 equivalents) until pH 8, and the solution was stirred at 22°C for 1 hour before the two phases were separated. The aqueous phase was extracted with toluene (2250mL, 3 volumes) and the combined organic phases were washed with 7.5% brine (1500mL, 2 volumes). The organic solution was fully concentrated at 65°C under reduced pressure to provide crude compound (A3) (696.9g, 100%, HPLC 98.4 area%, RT 14.96min) in an oily state.

[0589] Toluene (6000 mL, 8 volumes) was added to the crude compound (A3) (696.6 g, 805.9 mmol) and the solution was cooled to 0°C, after which 1 m NaHMDS in THF (3380 mL, 3380 mmol, 2.1 eq) was added over a 100-minute period, during which the temperature of the mixture did not exceed 5°C. The reaction mixture was stirred at 2°C for 3.5 hours, after which the solution was warmed to 20°C over a 13-minute period. The reaction mixture was then quenched by the addition of 5% brine (3750 mL, 5 volumes) and the mixture was stirred for 10 minutes before the two phases were separated. The organic phase was washed sequentially with 10% acetic acid (2310 mL, 4030 mmol, 2.5 eq) and water (3750 mL, 5 volumes), after which the organic phase was fully concentrated at 60°C under reduced pressure. Isopropanol (2250 mL, 3 volumes) was then added and the organic phase was fully concentrated again at 60°C under reduced pressure. Subsequently, isopropanol (750mL, 1 volume) was added and the solution was transferred to a premixed solution (22°C-premixed for 1 hour) of isopropanol (750mL, 1 volume), heptane (6000mL, 8 volumes) and acetyl chloride (229.2mL, 3220mmol, 2 equivalents), and precipitation was observed. The mixture was stirred at 20°C for 1 hour, after which the slurry was cooled to 4°C during 30 minutes and stirred at this temperature for 80 minutes. Then, the product was filtered out and the filter cake was washed with cold (4°C) heptane (750mL, 1 volume). The wet product was dried overnight at 50°C under vacuum. This provided compound (A4-HCl) (555.1g, 80%) as a white powder.

[0590] HPLC purity: 99.3 area%, 99.2 w / w%.

[0591] 1 H NMR (400 MHz, CDCl 3 )δ12.50(s,1H),7.05(s,1H),6.82(s,1H),5.99(m,2H),3.87(dd,J=15.8,6.7Hz,1H),3.6 5(m,1H),3.45(m,1H),3.20(ddd,J=11.0,9.7,4.4Hz,1H),3.08(tdd,J=12.7,4.9,2.5Hz, 1H),2.92(m,2H),2.77(tdd,J=12.0,8.5,3.1Hz,1H),2.49(m,1H),2.21(m,1H),1.84(m,2 H), 1.66 (dtd, J = 13.5, 11.7, 4.0Hz, 1H), 1.52 (m, 1H), 1.39 (s, 9H), 0.77 (t, J = 7.3Hz, 3H).

[0592] List of references

[0593] US 4543256

[0594] WO 2001 / 078713

[0595] WO 02 / 100377

[0596] WO 2009 / 026934,

[0597] WO 2009 / 026935

[0598] WO2010 / 097092

[0599] Alexander et Crutcher,(1990)Trends in Neuroscience 13:266-71;

[0600] Bibbiani et al.,Chase Experimental Neurology(2005),192:73-78;

[0601] Brückner and co-workers in Synthesis 2008,14:2229-2246;

[0602] Campbell et al.,Neuropharmacology(1982);21(10):953-961;

[0603] Cannon et al.,J.Heterocyclic Chem.(1980);17:1633-1636;

[0604] Delong,(1990)Trends in Neuroscience 13:281-5;

[0605] Fan et al.,Bioorg.Med.Chem.Lett.2008,18:6236-6239;

[0606] Gerfen et al,Science(1990)250:1429-32;

[0607] Giardina and Williams;CNS Drug Reviews(2001),Vol.7(3):305-316);

[0608] Grosset et al.,Acta Neurol Scand.(2013),128:166-171;

[0609] Hauser et al.,Movement Disorders(2016),Vol.32(9):1367-1372;

[0610] Kotsuki et al.,J.Org.Chem.1992,57:5036-5040);

[0611] Liu et al.,J.Med.Chem.(2006),49:1494-1498;

[0612] Liu et al.,Bioorganic Med.Chem.(2008),16:3438-3444;

[0613] S.Nishimura,Wiley 2001,Handbook of heterogeneoushydrogenation;

[0614] Poewe et al.,Nature Review,(2017)vol 3 article 17013:1-21;

[0615] Sprenger and Poewe,CNS Drugs(2013),27:259-272;

[0616] Sozio et al.,Exp.Opin.Drug Disc.(2012);7(5):385-406;

[0617] Stahl and Wermuth(Eds)“Handbook of Pharmaceutical salts.Properties,selection,and use”,Wiley-VCH,2008。

Claims

1. A compound having the following formula A5 or a salt thereof.

2. The compound according to claim 1, which is in the form of a tosylate salt.

3. A method for preparing a compound Ib having the formula Wherein compound Ib is prepared by a method comprising the following steps: Compound A5 or a salt thereof is reduced using a palladium catalyst according to the following reaction scheme to obtain Compound Ib or a salt thereof 4. The process according to claim 3, wherein compound A5-toluenesulfonate is used in step 5 to obtain compound Ib.

5. The method according to any one of claims 3 to 4, wherein an alcohol solvent is used in step 5.

6. The method according to any one of claims 3 to 5, wherein a solvent selected from the group consisting of MeOH, EtOH, IPA and 1-propanol is used in step 5.

7. The method according to any one of claims 3 to 6, wherein EtOH is used as solvent in step 5.

8. The process according to any one of claims 3 to 7, wherein step 5 is carried out at a temperature of 50°C to 100°C using a palladium catalyst.

9. The method according to claim 8, wherein step 5 is carried out at a temperature of 60°C to 80°C using a palladium catalyst.

10. The process according to claim 1, wherein step 5 is carried out using a palladium catalyst at a pressure of 3 to 6 bar.

11. The process according to claim 1, wherein step 5 is carried out at a temperature of 70°C and a pressure of 4 bar using a palladium catalyst.

12. A method for making Compound A5 or a salt thereof, comprising the following step 4: performing an intramolecular Friedel-Crafts acylation of Compound A4 to provide Compound A5 according to the following reaction scheme: Optionally compound A5 or a salt thereof is subsequently isolated.

13. The process of claim 12, wherein compound A5 is isolated as a tosylate salt.

14. A compound having the following formula A2 or a salt thereof.

15. A compound having the following formula A3 or a salt thereof.

16. A compound having the following formula A4 or a salt thereof.

17. A compound having the following formula a2i or a salt thereof.

18. A compound having the following formula a2ii or a salt thereof.